The debate over the abortion pill mifepristone is once again at the forefront of political and legal battles, with various court cases and Republican lawmakers seeking to impose restrictions. Meanwhile, the Food and Drug Administration (FDA) is currently conducting a review of the regulation and labeling of mifepristone, a drug that has a long-standing track record of safety and effectiveness.
Health and Human Services Secretary Robert F. Kennedy Jr. recently directed the FDA to conduct a comprehensive review of its regulations on mifepristone, a medication used in combination with misoprostol for the majority of abortions in the United States. Since its approval over two decades ago, mifepristone has been used by more than 8 million individuals.
Approved by the FDA in 2000 for medication abortion, mifepristone works by blocking progesterone, a hormone crucial for sustaining pregnancy. When used in conjunction with misoprostol, mifepristone effectively terminates early pregnancies up to 10 weeks following conception.
In a move to increase accessibility, the FDA permitted the administration of mifepristone at home through telemedicine visits and mail-order prescriptions starting in 2021. This change in regulations has led to a rise in the number of medication-induced abortions in recent years, possibly influenced by the Supreme Court’s decision to overturn Roe v. Wade in 2022.
However, Secretary Kennedy’s call for a new FDA review aims to reinstate the requirement for in-person dispensing of mifepristone, which would necessitate individuals to visit a clinic to obtain the medication.
Despite the FDA’s previous efforts to preserve convenient access to mifepristone, recent developments such as a Texas federal judge allowing three Republican-led states to proceed with a lawsuit to restrict access to the drug have raised concerns about future accessibility.
Mifepristone has a proven safety record both in Europe, where it has been used for nearly three decades, and in the U.S. Since its approval, only a small number of adverse events have been reported, with a mortality rate of less than 1%. Numerous studies have confirmed the safety and efficacy of mifepristone and misoprostol for terminating pregnancies.
While some non-peer-reviewed studies have raised questions about the safety of medication abortions, the overwhelming body of evidence supports the use of mifepristone as a safe and effective method for ending pregnancies.
As the FDA conducts its review of mifepristone, the outcome of ongoing court cases and the findings of the review ordered by Secretary Kennedy will determine the future of access to this crucial medication.
